| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 150 | 2021 | 625 | 16.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 118 | 2021 | 316 | 15.770 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 74 | 2020 | 290 | 8.360 |
Why?
|
| Antineoplastic Agents | 40 | 2013 | 218 | 5.680 |
Why?
|
| ErbB Receptors | 23 | 2018 | 72 | 3.000 |
Why?
|
| Quinazolines | 10 | 2012 | 24 | 2.120 |
Why?
|
| Carcinoma, Squamous Cell | 23 | 2018 | 178 | 2.110 |
Why?
|
| Paclitaxel | 25 | 2015 | 74 | 1.990 |
Why?
|
| Clinical Trials as Topic | 22 | 2020 | 324 | 1.840 |
Why?
|
| Biomarkers, Tumor | 15 | 2021 | 175 | 1.830 |
Why?
|
| Neoplasm Staging | 51 | 2021 | 340 | 1.720 |
Why?
|
| Neoplasm Recurrence, Local | 19 | 2019 | 184 | 1.610 |
Why?
|
| Cisplatin | 38 | 2016 | 91 | 1.550 |
Why?
|
| Humans | 205 | 2021 | 29337 | 1.530 |
Why?
|
| Carboplatin | 23 | 2015 | 49 | 1.340 |
Why?
|
| Adenocarcinoma | 20 | 2018 | 189 | 1.320 |
Why?
|
| Antibodies, Monoclonal, Humanized | 16 | 2019 | 113 | 1.180 |
Why?
|
| Prognosis | 35 | 2021 | 840 | 1.180 |
Why?
|
| Bevacizumab | 10 | 2016 | 27 | 1.180 |
Why?
|
| Middle Aged | 106 | 2020 | 9823 | 1.160 |
Why?
|
| Aged | 99 | 2019 | 9448 | 1.120 |
Why?
|
| Female | 118 | 2020 | 16197 | 1.110 |
Why?
|
| Pemetrexed | 10 | 2016 | 14 | 1.080 |
Why?
|
| Weight Gain | 3 | 2016 | 66 | 1.070 |
Why?
|
| Treatment Outcome | 41 | 2021 | 3478 | 1.060 |
Why?
|
| Disease-Free Survival | 22 | 2018 | 175 | 1.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 10 | 2016 | 23 | 1.030 |
Why?
|
| Male | 106 | 2019 | 15621 | 1.020 |
Why?
|
| Survival Rate | 32 | 2019 | 349 | 0.960 |
Why?
|
| Taxoids | 6 | 2008 | 14 | 0.940 |
Why?
|
| Etoposide | 22 | 2015 | 48 | 0.930 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2020 | 47 | 0.920 |
Why?
|
| Antibodies, Monoclonal | 11 | 2016 | 260 | 0.900 |
Why?
|
| Antineoplastic Agents, Phytogenic | 9 | 2008 | 19 | 0.880 |
Why?
|
| Eligibility Determination | 2 | 2020 | 5 | 0.850 |
Why?
|
| Adult | 76 | 2019 | 8601 | 0.840 |
Why?
|
| Apoptosis | 12 | 2009 | 251 | 0.840 |
Why?
|
| Survival Analysis | 21 | 2021 | 298 | 0.810 |
Why?
|
| Chemoradiotherapy | 4 | 2015 | 67 | 0.780 |
Why?
|
| Proteomics | 3 | 2020 | 91 | 0.780 |
Why?
|
| Drug Administration Schedule | 20 | 2015 | 223 | 0.780 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2020 | 6 | 0.750 |
Why?
|
| Patient Selection | 8 | 2021 | 232 | 0.750 |
Why?
|
| Combined Modality Therapy | 31 | 2011 | 364 | 0.740 |
Why?
|
| Mutation | 11 | 2018 | 383 | 0.730 |
Why?
|
| Ecosystem | 1 | 2020 | 27 | 0.730 |
Why?
|
| Quality of Life | 11 | 2016 | 662 | 0.700 |
Why?
|
| Carcinoma, Small Cell | 12 | 2009 | 71 | 0.700 |
Why?
|
| Small Cell Lung Carcinoma | 5 | 2018 | 11 | 0.700 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2019 | 75 | 0.700 |
Why?
|
| Gene Dosage | 3 | 2018 | 23 | 0.690 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2021 | 18 | 0.670 |
Why?
|
| Molecular Targeted Therapy | 3 | 2018 | 31 | 0.570 |
Why?
|
| Carcinoma, Large Cell | 5 | 2018 | 15 | 0.570 |
Why?
|
| Aged, 80 and over | 33 | 2018 | 4851 | 0.530 |
Why?
|
| Immunotherapy | 4 | 2021 | 62 | 0.530 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2011 | 10 | 0.510 |
Why?
|
| Disease Progression | 15 | 2014 | 787 | 0.510 |
Why?
|
| Kidney Neoplasms | 3 | 2019 | 60 | 0.510 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2018 | 340 | 0.490 |
Why?
|
| Neoplasms | 9 | 2011 | 247 | 0.480 |
Why?
|
| Polyglutamic Acid | 3 | 2008 | 4 | 0.480 |
Why?
|
| Follow-Up Studies | 15 | 2019 | 1830 | 0.470 |
Why?
|
| Retrospective Studies | 22 | 2018 | 3273 | 0.460 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2019 | 35 | 0.450 |
Why?
|
| Signal Transduction | 5 | 2013 | 482 | 0.450 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2018 | 162 | 0.450 |
Why?
|
| Erlotinib Hydrochloride | 6 | 2018 | 16 | 0.440 |
Why?
|
| Guanine | 7 | 2015 | 11 | 0.440 |
Why?
|
| Glutamates | 7 | 2015 | 17 | 0.440 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 18 | 0.430 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 48 | 0.410 |
Why?
|
| Megestrol | 12 | 1996 | 12 | 0.370 |
Why?
|
| Autoantibodies | 3 | 2021 | 100 | 0.370 |
Why?
|
| Radiotherapy | 6 | 2009 | 50 | 0.360 |
Why?
|
| Fluorouracil | 12 | 2000 | 75 | 0.350 |
Why?
|
| Neovascularization, Pathologic | 3 | 2014 | 56 | 0.350 |
Why?
|
| Cetuximab | 4 | 2013 | 8 | 0.350 |
Why?
|
| Breast Neoplasms | 15 | 1998 | 329 | 0.350 |
Why?
|
| Vinblastine | 6 | 2009 | 8 | 0.340 |
Why?
|
| Drug Delivery Systems | 2 | 2010 | 37 | 0.330 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 30 | 0.330 |
Why?
|
| Uterine Cervical Neoplasms | 7 | 1990 | 51 | 0.320 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2008 | 22 | 0.320 |
Why?
|
| Carcinoma, Bronchogenic | 6 | 1988 | 11 | 0.320 |
Why?
|
| Morpholines | 1 | 2007 | 14 | 0.310 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2007 | 21 | 0.310 |
Why?
|
| Neoplasm Metastasis | 14 | 2014 | 101 | 0.310 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2007 | 7 | 0.310 |
Why?
|
| Macromolecular Substances | 1 | 2007 | 17 | 0.310 |
Why?
|
| Pneumonectomy | 6 | 2012 | 67 | 0.300 |
Why?
|
| Lipoxygenase Inhibitors | 7 | 2003 | 13 | 0.290 |
Why?
|
| Postoperative Complications | 6 | 2019 | 957 | 0.280 |
Why?
|
| Sulfonamides | 3 | 2012 | 54 | 0.280 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2005 | 2 | 0.280 |
Why?
|
| Enzyme Inhibitors | 3 | 2004 | 145 | 0.280 |
Why?
|
| Melanoma | 1 | 2006 | 52 | 0.270 |
Why?
|
| Receptors, Progesterone | 10 | 1988 | 27 | 0.270 |
Why?
|
| Lung | 4 | 2018 | 154 | 0.270 |
Why?
|
| Aniline Compounds | 3 | 2012 | 41 | 0.260 |
Why?
|
| Indoles | 8 | 2003 | 48 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 2012 | 28 | 0.250 |
Why?
|
| United States Food and Drug Administration | 2 | 2020 | 70 | 0.250 |
Why?
|
| Receptors, Estrogen | 9 | 1988 | 58 | 0.240 |
Why?
|
| Proportional Hazards Models | 6 | 2013 | 340 | 0.240 |
Why?
|
| United States | 6 | 2020 | 2333 | 0.230 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2000 | 26 | 0.230 |
Why?
|
| Biomarkers | 4 | 2018 | 689 | 0.220 |
Why?
|
| Remission Induction | 8 | 2010 | 96 | 0.220 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2018 | 16 | 0.220 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2002 | 8 | 0.210 |
Why?
|
| Matrix Metalloproteinases | 1 | 2002 | 22 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 100 | 0.200 |
Why?
|
| Camptothecin | 1 | 2001 | 3 | 0.200 |
Why?
|
| Immunohistochemistry | 4 | 2012 | 391 | 0.200 |
Why?
|
| Thymoma | 4 | 1996 | 13 | 0.200 |
Why?
|
| Thymus Neoplasms | 4 | 1996 | 12 | 0.200 |
Why?
|
| Mediastinal Neoplasms | 2 | 1991 | 12 | 0.190 |
Why?
|
| Deoxycytidine | 4 | 2016 | 31 | 0.190 |
Why?
|
| DNA Methylation | 2 | 2012 | 124 | 0.190 |
Why?
|
| Lymphatic Metastasis | 7 | 2010 | 81 | 0.190 |
Why?
|
| Esophageal Neoplasms | 2 | 2019 | 45 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 2 | 2011 | 53 | 0.190 |
Why?
|
| Stakeholder Participation | 1 | 2020 | 9 | 0.190 |
Why?
|
| Diarrhea | 3 | 2007 | 48 | 0.190 |
Why?
|
| Research Personnel | 1 | 2020 | 20 | 0.190 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2019 | 3 | 0.180 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2009 | 25 | 0.180 |
Why?
|
| Drug Evaluation | 11 | 1992 | 52 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2016 | 31 | 0.180 |
Why?
|
| Salvage Therapy | 1 | 2019 | 36 | 0.180 |
Why?
|
| Esophagectomy | 1 | 2019 | 21 | 0.180 |
Why?
|
| Regression Analysis | 5 | 2009 | 298 | 0.180 |
Why?
|
| Sarcopenia | 1 | 2019 | 26 | 0.170 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 41 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2008 | 65 | 0.160 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2010 | 16 | 0.160 |
Why?
|
| Syndecan-1 | 1 | 2018 | 8 | 0.160 |
Why?
|
| Immunoassay | 1 | 2018 | 41 | 0.160 |
Why?
|
| Nerve Growth Factors | 1 | 2018 | 44 | 0.160 |
Why?
|
| Risk Assessment | 5 | 2011 | 679 | 0.160 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 83 | 0.150 |
Why?
|
| Models, Statistical | 1 | 1998 | 132 | 0.150 |
Why?
|
| Pteridines | 1 | 2016 | 1 | 0.150 |
Why?
|
| Lung Diseases | 1 | 1997 | 46 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 9 | 2003 | 145 | 0.150 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 17 | 0.150 |
Why?
|
| Myasthenia Gravis | 1 | 2017 | 11 | 0.150 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2018 | 12 | 0.150 |
Why?
|
| Cell Division | 9 | 2003 | 113 | 0.150 |
Why?
|
| Genes, bcl-2 | 2 | 2011 | 3 | 0.150 |
Why?
|
| Palliative Care | 2 | 2015 | 145 | 0.150 |
Why?
|
| Drug Discovery | 1 | 2016 | 20 | 0.140 |
Why?
|
| Cachexia | 1 | 2016 | 11 | 0.140 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 349 | 0.140 |
Why?
|
| Radiotherapy Dosage | 7 | 2014 | 113 | 0.140 |
Why?
|
| Exanthema | 2 | 2007 | 15 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2012 | 22 | 0.140 |
Why?
|
| Cohort Studies | 8 | 2015 | 1939 | 0.140 |
Why?
|
| Interleukin-2 | 2 | 2009 | 66 | 0.130 |
Why?
|
| Prostatic Neoplasms | 5 | 1996 | 106 | 0.130 |
Why?
|
| Administration, Oral | 5 | 2011 | 140 | 0.130 |
Why?
|
| Isoxazoles | 1 | 1994 | 16 | 0.130 |
Why?
|
| Cell Survival | 5 | 2013 | 169 | 0.120 |
Why?
|
| Predictive Value of Tests | 4 | 2009 | 521 | 0.120 |
Why?
|
| Radiotherapy, Conformal | 1 | 2014 | 19 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2013 | 8 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2016 | 428 | 0.120 |
Why?
|
| Genes, p16 | 1 | 2012 | 4 | 0.110 |
Why?
|
| Triazoles | 1 | 2013 | 29 | 0.110 |
Why?
|
| Thrombocytopenia | 2 | 2012 | 30 | 0.110 |
Why?
|
| Vinca Alkaloids | 1 | 2012 | 1 | 0.110 |
Why?
|
| Folate Receptor 1 | 1 | 2012 | 1 | 0.110 |
Why?
|
| Early Detection of Cancer | 2 | 2010 | 79 | 0.110 |
Why?
|
| Folic Acid | 1 | 2012 | 16 | 0.110 |
Why?
|
| Nogalamycin | 1 | 1992 | 1 | 0.110 |
Why?
|
| Young Adult | 3 | 2014 | 1932 | 0.110 |
Why?
|
| Platinum Compounds | 2 | 2007 | 2 | 0.110 |
Why?
|
| Area Under Curve | 2 | 2009 | 66 | 0.110 |
Why?
|
| Infusions, Intravenous | 7 | 2006 | 76 | 0.110 |
Why?
|
| Adolescent | 3 | 2014 | 2279 | 0.110 |
Why?
|
| Radiation Injuries | 3 | 2015 | 34 | 0.110 |
Why?
|
| Pyrimidines | 2 | 2019 | 21 | 0.100 |
Why?
|
| C-Peptide | 1 | 2011 | 7 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2011 | 11 | 0.100 |
Why?
|
| Animals | 8 | 2010 | 4552 | 0.100 |
Why?
|
| Cell Death | 3 | 2003 | 61 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 3 | 2002 | 75 | 0.100 |
Why?
|
| Research Design | 4 | 2016 | 212 | 0.100 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1991 | 8 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 54 | 0.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2010 | 29 | 0.100 |
Why?
|
| Gene Amplification | 1 | 2010 | 19 | 0.100 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 13 | 0.100 |
Why?
|
| Hematologic Tests | 1 | 2010 | 6 | 0.100 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 10 | 0.100 |
Why?
|
| Xanthine Dehydrogenase | 1 | 2010 | 6 | 0.100 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2010 | 21 | 0.090 |
Why?
|
| Leukocyte Count | 4 | 2017 | 92 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 32 | 0.090 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 4 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 21 | 0.090 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2014 | 67 | 0.090 |
Why?
|
| Diphtheria Toxin | 1 | 2009 | 2 | 0.090 |
Why?
|
| Treatment Failure | 3 | 2016 | 159 | 0.090 |
Why?
|
| Neutropenia | 1 | 2009 | 21 | 0.090 |
Why?
|
| Colonic Neoplasms | 7 | 1988 | 66 | 0.090 |
Why?
|
| Smoking | 3 | 2016 | 194 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 4 | 2003 | 142 | 0.090 |
Why?
|
| Forecasting | 2 | 2001 | 117 | 0.090 |
Why?
|
| B7-H1 Antigen | 2 | 2021 | 13 | 0.090 |
Why?
|
| Cyclophosphamide | 6 | 1996 | 55 | 0.090 |
Why?
|
| Organoplatinum Compounds | 3 | 2002 | 7 | 0.090 |
Why?
|
| Fatigue | 1 | 2009 | 59 | 0.080 |
Why?
|
| Piperidines | 1 | 2008 | 32 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2009 | 70 | 0.080 |
Why?
|
| Interferon Type I | 2 | 1986 | 18 | 0.080 |
Why?
|
| Logistic Models | 2 | 2007 | 407 | 0.080 |
Why?
|
| Celecoxib | 1 | 2008 | 5 | 0.080 |
Why?
|
| Peptic Ulcer | 1 | 2008 | 6 | 0.080 |
Why?
|
| Megestrol Acetate | 9 | 1988 | 9 | 0.080 |
Why?
|
| In Situ Hybridization | 1 | 2008 | 46 | 0.080 |
Why?
|
| Razoxane | 1 | 1988 | 1 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 33 | 0.080 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1998 | 12 | 0.080 |
Why?
|
| Anemia | 1 | 2009 | 97 | 0.080 |
Why?
|
| Epothilones | 1 | 2007 | 2 | 0.080 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2003 | 14 | 0.080 |
Why?
|
| Aneuploidy | 1 | 2007 | 3 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2008 | 44 | 0.080 |
Why?
|
| Algorithms | 4 | 2010 | 400 | 0.080 |
Why?
|
| Models, Theoretical | 2 | 2005 | 91 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 770 | 0.080 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 56 | 0.080 |
Why?
|
| Dactinomycin | 2 | 2003 | 7 | 0.080 |
Why?
|
| Piperazines | 1 | 1988 | 90 | 0.080 |
Why?
|
| Carcinoma | 3 | 1996 | 57 | 0.080 |
Why?
|
| Time Factors | 4 | 2018 | 1616 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2011 | 62 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 161 | 0.070 |
Why?
|
| Antigens, Neoplasm | 2 | 2021 | 37 | 0.070 |
Why?
|
| Analysis of Variance | 4 | 2011 | 321 | 0.070 |
Why?
|
| Doxorubicin | 6 | 1996 | 45 | 0.070 |
Why?
|
| Endpoint Determination | 1 | 2006 | 28 | 0.070 |
Why?
|
| Proteasome Inhibitors | 1 | 2005 | 3 | 0.070 |
Why?
|
| Boronic Acids | 1 | 2005 | 4 | 0.070 |
Why?
|
| Bortezomib | 1 | 2005 | 5 | 0.070 |
Why?
|
| Pyrazines | 1 | 2005 | 10 | 0.070 |
Why?
|
| Drug Approval | 1 | 2006 | 30 | 0.070 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2005 | 8 | 0.070 |
Why?
|
| Ligands | 1 | 2005 | 55 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2011 | 437 | 0.070 |
Why?
|
| Cause of Death | 2 | 2009 | 65 | 0.070 |
Why?
|
| Multivariate Analysis | 4 | 2011 | 324 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2005 | 36 | 0.070 |
Why?
|
| Pilot Projects | 5 | 2000 | 394 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 101 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2011 | 75 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 88 | 0.070 |
Why?
|
| Tamoxifen | 5 | 1988 | 30 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 107 | 0.060 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2004 | 27 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 215 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2013 | 264 | 0.060 |
Why?
|
| Radiometry | 1 | 2004 | 38 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2018 | 1811 | 0.060 |
Why?
|
| Hematologic Diseases | 2 | 2002 | 14 | 0.060 |
Why?
|
| Digestive System Neoplasms | 1 | 1984 | 5 | 0.060 |
Why?
|
| Prostate | 3 | 1997 | 33 | 0.060 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2003 | 9 | 0.060 |
Why?
|
| Aminoquinolines | 1 | 2003 | 1 | 0.060 |
Why?
|
| Organic Chemicals | 1 | 2003 | 8 | 0.060 |
Why?
|
| Recurrence | 2 | 2016 | 350 | 0.060 |
Why?
|
| Pyrroles | 1 | 2003 | 17 | 0.060 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 29 | 0.060 |
Why?
|
| Sensitivity and Specificity | 4 | 2009 | 553 | 0.060 |
Why?
|
| Health Status Indicators | 1 | 2004 | 78 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2002 | 58 | 0.060 |
Why?
|
| Aminoacridines | 1 | 1983 | 2 | 0.060 |
Why?
|
| Pyridines | 2 | 2019 | 42 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2004 | 89 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2004 | 222 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2003 | 14 | 0.060 |
Why?
|
| Injections, Intravenous | 3 | 1999 | 56 | 0.060 |
Why?
|
| Lymphocytes | 2 | 2017 | 110 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2012 | 219 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2002 | 68 | 0.050 |
Why?
|
| Radiation Pneumonitis | 2 | 2015 | 4 | 0.050 |
Why?
|
| Mitomycins | 4 | 1989 | 4 | 0.050 |
Why?
|
| Health Status | 1 | 2003 | 227 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2002 | 124 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2001 | 4 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 18 | 0.050 |
Why?
|
| Observer Variation | 1 | 2021 | 118 | 0.050 |
Why?
|
| Genome | 1 | 2000 | 15 | 0.050 |
Why?
|
| Adrenalectomy | 1 | 2000 | 2 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2000 | 11 | 0.050 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2000 | 11 | 0.050 |
Why?
|
| Dyspnea | 2 | 2015 | 37 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 2 | 2011 | 16 | 0.050 |
Why?
|
| DNA Damage | 3 | 2008 | 30 | 0.050 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 1997 | 9 | 0.050 |
Why?
|
| Furans | 1 | 2019 | 3 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1999 | 11 | 0.050 |
Why?
|
| Interferon-beta | 1 | 1999 | 7 | 0.050 |
Why?
|
| Oncogenes | 1 | 1999 | 13 | 0.050 |
Why?
|
| Methotrexate | 3 | 1989 | 41 | 0.040 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2018 | 1 | 0.040 |
Why?
|
| Platelet Count | 3 | 1989 | 20 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 1999 | 12 | 0.040 |
Why?
|
| North America | 1 | 2018 | 38 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 45 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 36 | 0.040 |
Why?
|
| Liver Neoplasms | 3 | 2005 | 103 | 0.040 |
Why?
|
| Interferons | 1 | 1998 | 13 | 0.040 |
Why?
|
| Random Allocation | 4 | 1986 | 146 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2010 | 638 | 0.040 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 1986 | 5 | 0.040 |
Why?
|
| Echinomycin | 1 | 1998 | 1 | 0.040 |
Why?
|
| Trimetrexate | 1 | 1998 | 1 | 0.040 |
Why?
|
| DNA, Neoplasm | 2 | 1996 | 25 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 89 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 1996 | 146 | 0.040 |
Why?
|
| Phenotype | 1 | 2018 | 355 | 0.040 |
Why?
|
| Age Factors | 3 | 2012 | 843 | 0.040 |
Why?
|
| Agranulocytosis | 1 | 1996 | 5 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 29 | 0.040 |
Why?
|
| Fadrozole | 1 | 1996 | 1 | 0.040 |
Why?
|
| Body Weight | 1 | 2017 | 133 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2002 | 1184 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 441 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1996 | 34 | 0.040 |
Why?
|
| Neutrophils | 1 | 2017 | 117 | 0.040 |
Why?
|
| Flow Cytometry | 3 | 2003 | 198 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 1998 | 1442 | 0.040 |
Why?
|
| Stem Cells | 1 | 1996 | 46 | 0.040 |
Why?
|
| Hemoptysis | 1 | 2015 | 8 | 0.030 |
Why?
|
| Pneumonia | 1 | 1996 | 67 | 0.030 |
Why?
|
| Esophagitis | 1 | 2015 | 11 | 0.030 |
Why?
|
| Cough | 1 | 2015 | 12 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 16 | 0.030 |
Why?
|
| Chest Pain | 1 | 2015 | 24 | 0.030 |
Why?
|
| Calcium | 2 | 1997 | 491 | 0.030 |
Why?
|
| Drug Tolerance | 1 | 1995 | 12 | 0.030 |
Why?
|
| Thorax | 1 | 1995 | 12 | 0.030 |
Why?
|
| Teniposide | 1 | 1995 | 2 | 0.030 |
Why?
|
| Gallium | 1 | 1995 | 4 | 0.030 |
Why?
|
| Imides | 1 | 1995 | 2 | 0.030 |
Why?
|
| Isoquinolines | 1 | 1995 | 14 | 0.030 |
Why?
|
| Drugs, Investigational | 1 | 1995 | 8 | 0.030 |
Why?
|
| DNA Repair | 2 | 2008 | 7 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 1995 | 227 | 0.030 |
Why?
|
| Vincristine | 2 | 1992 | 26 | 0.030 |
Why?
|
| Drug Resistance | 1 | 1994 | 55 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 498 | 0.030 |
Why?
|
| Optics and Photonics | 1 | 1994 | 2 | 0.030 |
Why?
|
| S Phase | 1 | 1994 | 10 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2015 | 97 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 1994 | 125 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 1994 | 78 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 4 | 0.030 |
Why?
|
| Protein Kinase C beta | 1 | 2013 | 7 | 0.030 |
Why?
|
| Proteins | 2 | 1985 | 72 | 0.030 |
Why?
|
| Diet | 1 | 2015 | 174 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 7 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2013 | 10 | 0.030 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2013 | 7 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2013 | 44 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 109 | 0.030 |
Why?
|
| Protein Binding | 1 | 2013 | 127 | 0.030 |
Why?
|
| Biopsy | 1 | 1994 | 234 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2013 | 159 | 0.030 |
Why?
|
| Procarbazine | 2 | 1989 | 3 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 28 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2013 | 105 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2012 | 30 | 0.030 |
Why?
|
| Menogaril | 1 | 1992 | 1 | 0.030 |
Why?
|
| Drug Therapy, Combination | 3 | 1999 | 241 | 0.030 |
Why?
|
| Child, Preschool | 1 | 1994 | 642 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 74 | 0.030 |
Why?
|
| Illinois | 1 | 2012 | 241 | 0.030 |
Why?
|
| Genotype | 1 | 2013 | 405 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2009 | 135 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 501 | 0.030 |
Why?
|
| Rectal Neoplasms | 2 | 1988 | 19 | 0.030 |
Why?
|
| Misonidazole | 1 | 1990 | 2 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 9 | 0.020 |
Why?
|
| Serum | 1 | 2010 | 9 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 26 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2010 | 10 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2010 | 3 | 0.020 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2010 | 4 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2010 | 6 | 0.020 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2010 | 6 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 40 | 0.020 |
Why?
|
| CpG Islands | 1 | 2010 | 34 | 0.020 |
Why?
|
| Cadherins | 1 | 2010 | 31 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 50 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 80 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 99 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 75 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2009 | 26 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1989 | 63 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 2 | 1988 | 24 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 29 | 0.020 |
Why?
|
| Vindesine | 2 | 1986 | 3 | 0.020 |
Why?
|
| Nervous System Neoplasms | 1 | 1988 | 3 | 0.020 |
Why?
|
| Endocrine System Diseases | 1 | 1988 | 3 | 0.020 |
Why?
|
| California | 1 | 2008 | 31 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1985 | 38 | 0.020 |
Why?
|
| Molecular Weight | 2 | 1985 | 45 | 0.020 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2008 | 1 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 1988 | 33 | 0.020 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2007 | 3 | 0.020 |
Why?
|
| Bone Neoplasms | 2 | 1988 | 101 | 0.020 |
Why?
|
| Piroxicam | 1 | 1987 | 5 | 0.020 |
Why?
|
| Receptors, Steroid | 1 | 1987 | 3 | 0.020 |
Why?
|
| Altretamine | 1 | 1986 | 1 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1986 | 50 | 0.020 |
Why?
|
| Radiation Protection | 1 | 2005 | 5 | 0.020 |
Why?
|
| Menopause | 3 | 1996 | 134 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 2 | 1984 | 133 | 0.020 |
Why?
|
| Models, Biological | 2 | 1999 | 343 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2005 | 48 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2005 | 39 | 0.020 |
Why?
|
| Sarcoma | 1 | 1986 | 65 | 0.020 |
Why?
|
| Rosaniline Dyes | 1 | 1985 | 1 | 0.020 |
Why?
|
| Nomograms | 1 | 2005 | 5 | 0.020 |
Why?
|
| Prostatic Hyperplasia | 1 | 1985 | 17 | 0.020 |
Why?
|
| Relative Biological Effectiveness | 1 | 2004 | 5 | 0.020 |
Why?
|
| Body Burden | 1 | 2004 | 9 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2004 | 31 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1985 | 73 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2005 | 65 | 0.020 |
Why?
|
| Hepatectomy | 1 | 1984 | 55 | 0.020 |
Why?
|
| Nucleosomes | 1 | 2003 | 3 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2003 | 7 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2003 | 6 | 0.010 |
Why?
|
| Women's Health | 1 | 2006 | 246 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 1984 | 30 | 0.010 |
Why?
|
| Caspases | 1 | 2003 | 32 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2003 | 44 | 0.010 |
Why?
|
| Molybdenum | 2 | 1980 | 22 | 0.010 |
Why?
|
| Cytosol | 2 | 1980 | 62 | 0.010 |
Why?
|
| Amsacrine | 1 | 1983 | 2 | 0.010 |
Why?
|
| Sleep Stages | 1 | 2002 | 34 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1983 | 32 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 788 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1982 | 49 | 0.010 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 1981 | 2 | 0.010 |
Why?
|
| Spin Labels | 1 | 2001 | 2 | 0.010 |
Why?
|
| Nitrogen Oxides | 1 | 2001 | 2 | 0.010 |
Why?
|
| Cyclic N-Oxides | 1 | 2001 | 5 | 0.010 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1981 | 8 | 0.010 |
Why?
|
| Amides | 1 | 2001 | 21 | 0.010 |
Why?
|
| Apudoma | 1 | 1981 | 2 | 0.010 |
Why?
|
| Psychometrics | 1 | 2002 | 262 | 0.010 |
Why?
|
| DNA Replication | 1 | 2000 | 12 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2000 | 48 | 0.010 |
Why?
|
| Genes, cdc | 1 | 1999 | 1 | 0.010 |
Why?
|
| Ribonucleases | 1 | 1999 | 9 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1999 | 28 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 145 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1999 | 170 | 0.010 |
Why?
|
| Free Radicals | 1 | 1999 | 9 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 1999 | 11 | 0.010 |
Why?
|
| Reperfusion Injury | 1 | 1999 | 8 | 0.010 |
Why?
|
| Demography | 1 | 1999 | 77 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1999 | 35 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1999 | 323 | 0.010 |
Why?
|
| Intercalating Agents | 1 | 1998 | 1 | 0.010 |
Why?
|
| Risk Factors | 1 | 2004 | 2443 | 0.010 |
Why?
|
| Amiloride | 1 | 1997 | 5 | 0.010 |
Why?
|
| Fura-2 | 1 | 1997 | 4 | 0.010 |
Why?
|
| Fluoresceins | 1 | 1997 | 8 | 0.010 |
Why?
|
| Trypsin | 1 | 1997 | 6 | 0.010 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1996 | 3 | 0.010 |
Why?
|
| DNA | 1 | 1997 | 125 | 0.010 |
Why?
|
| Mitosis | 1 | 1996 | 9 | 0.010 |
Why?
|
| G2 Phase | 1 | 1996 | 4 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1996 | 59 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1997 | 148 | 0.010 |
Why?
|
| Prostaglandins | 1 | 1996 | 4 | 0.010 |
Why?
|
| Genes, Homeobox | 1 | 1996 | 5 | 0.010 |
Why?
|
| Telomerase | 1 | 1996 | 9 | 0.010 |
Why?
|
| Inflammation | 1 | 1999 | 344 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1997 | 127 | 0.010 |
Why?
|
| Cell Count | 1 | 1996 | 99 | 0.010 |
Why?
|
| Biological Evolution | 1 | 1996 | 23 | 0.010 |
Why?
|
| Ifosfamide | 1 | 1995 | 8 | 0.010 |
Why?
|
| Progesterone | 2 | 1988 | 26 | 0.010 |
Why?
|
| Naphthalimides | 1 | 1995 | 2 | 0.010 |
Why?
|
| Adenine | 1 | 1995 | 5 | 0.010 |
Why?
|
| Organophosphonates | 1 | 1995 | 5 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1996 | 503 | 0.010 |
Why?
|
| Isoelectric Focusing | 2 | 1985 | 4 | 0.010 |
Why?
|
| HIV Infections | 1 | 1999 | 970 | 0.010 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1990 | 10 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1988 | 70 | 0.010 |
Why?
|
| Mitomycin | 1 | 1988 | 12 | 0.010 |
Why?
|
| Patient Participation | 1 | 1988 | 52 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1988 | 50 | 0.010 |
Why?
|
| Axilla | 1 | 1987 | 11 | 0.000 |
Why?
|
| Killer Cells, Natural | 1 | 1987 | 91 | 0.000 |
Why?
|
| Colon | 1 | 1988 | 148 | 0.000 |
Why?
|
| Monocytes | 1 | 1987 | 116 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1987 | 209 | 0.000 |
Why?
|
| Indicators and Reagents | 1 | 1985 | 14 | 0.000 |
Why?
|
| Actuarial Analysis | 1 | 1984 | 14 | 0.000 |
Why?
|
| Risk | 1 | 1984 | 217 | 0.000 |
Why?
|
| Electrophoresis | 1 | 1983 | 15 | 0.000 |
Why?
|
| Radiography | 1 | 1985 | 678 | 0.000 |
Why?
|
| Maytansine | 1 | 1982 | 3 | 0.000 |
Why?
|
| Streptozocin | 1 | 1982 | 6 | 0.000 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1982 | 6 | 0.000 |
Why?
|
| Leukopenia | 1 | 1982 | 8 | 0.000 |
Why?
|
| Cytoplasmic Granules | 1 | 1981 | 9 | 0.000 |
Why?
|
| Castration | 1 | 1981 | 4 | 0.000 |
Why?
|
| Pelvic Neoplasms | 1 | 1981 | 7 | 0.000 |
Why?
|
| Charcoal | 1 | 1980 | 2 | 0.000 |
Why?
|
| Dextrans | 1 | 1980 | 5 | 0.000 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1980 | 13 | 0.000 |
Why?
|
| Tritium | 1 | 1980 | 14 | 0.000 |
Why?
|
| Uterus | 1 | 1980 | 15 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1981 | 124 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1980 | 213 | 0.000 |
Why?
|